HAIER BIOMEDICAL(SH:688139)2023-03-28 16:00Financial Performance - In 2022, the company's operating income reached ¥2,864,044,617.29, representing a year-on-year increase of 34.72%[32]. - The net profit attributable to shareholders was ¥600,791,263.18, a decrease of 28.90% compared to the previous year[32]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥532,875,645.95, an increase of 27.47% year-on-year[32]. - The company's total assets at the end of 2022 amounted to ¥5,488,995,841.72, reflecting a 12.02% increase from the previous year[32]. - The basic earnings per share for 2022 was ¥1.89, down 29.21% from ¥2.67 in 2021[32]. - The company's net assets attributable to shareholders increased by 10.98% to ¥4,020,637,920.82 by the end of 2022[32]. - The company reported a net cash flow from operating activities of ¥632,429,327.27, an increase of 6.87% year-on-year[32]. Dividend and Share Capital - The company plans to distribute a cash dividend of 4.5 RMB per 10 shares, totaling approximately 142.42 million RMB (including tax) based on a total share capital of 317,952,508 shares as of December 31, 2022[7]. - The company has a total share capital of 317,952,508 shares, with 1,459,586 shares held in a repurchase account, affecting the dividend distribution calculation[7]. - The company has a total share count of 317,952,508 after the issuance of 880,750 new shares, with 58.15% being unrestricted circulating shares[149]. - The company plans to repurchase up to 1 million shares, which would account for approximately 0.32% of the total share capital, with a maximum repurchase price of 100 RMB per share[194]. - The lower limit of the repurchase plan estimates around 500,000 shares, representing about 0.16% of the total share capital[194]. Corporate Governance - The audit report issued by Ernst & Young Huaming confirms the financial statements' accuracy and completeness, providing assurance to stakeholders[6]. - The company has confirmed that all board members attended the board meeting, ensuring governance and oversight in decision-making processes[10]. - The company has not disclosed any special arrangements in corporate governance, indicating standard practices are in place[15]. - The company has not reported any non-operational fund occupation by controlling shareholders or related parties, ensuring financial integrity[15]. - The company has not violated decision-making procedures for external guarantees, indicating adherence to regulatory compliance[15]. - The company has not disclosed any related party transactions among the top ten shareholders, ensuring transparency in ownership[188]. - The company is committed to maintaining its corporate governance standards, as evidenced by the absence of undisclosed related party relationships among shareholders[188]. Strategic Development and Future Plans - The company has outlined its future plans and strategic development in the annual report, although these do not constitute binding commitments to investors[12]. - The company is actively expanding its market presence, particularly in the life sciences and healthcare sectors, driven by national strategies promoting technological innovation and healthcare services[74]. - The company has established a "dual carbon" task force to promote green and low-carbon development across various departments[38]. - The company has a commitment to not transfer or reduce its shareholdings for a period of three months starting from October 25, 2022[58]. - The company has committed to limiting the annual transfer of shares to no more than 25% of the total shares held during its tenure as a director or senior management[58]. Research and Development - The company invested 10.21% of its operating income in R&D, a decrease of 0.91 percentage points from the previous year[32]. - The company introduced over 30 new products in microbiological culture media and protein expression technology, expanding its market in biopharmaceutical research and industrial production[90]. - The company increased its patent portfolio by 50%, with a total of 271 new patents filed in 2022, including 11 invention patents[90]. - The company has made significant advancements in automation technology, including a self-innovated -80℃ automated biological sample storage technology[87]. - The company is focused on enhancing its technological capabilities to meet the growing demand for comprehensive solutions in biological experiments, drug development, and medical services[74]. Market Expansion - The company's overseas market revenue reached 83,389.89 million yuan, representing a year-on-year growth of 56.45%[82]. - The domestic market generated revenue of CNY 2,021.53 million, reflecting a year-on-year growth of 27.50%[175]. - The company expanded its overseas distribution network to over 700, covering 8 new countries in Central and Eastern Europe[176]. - The company has established long-term partnerships with over 40 international organizations, including WHO and UNICEF[153]. - The company has successfully broken foreign monopolies in biomedical low-temperature technology and has received the only National Science and Technology Progress Award in the industry[152]. Operational Efficiency - The company has optimized its entire value chain through digitalization, enhancing operational efficiency across various departments[151]. - The company maintains a complete control process from customer demand collection to after-sales service, ensuring operational consistency[158]. - The company has implemented a production management system to ensure product quality meets regulatory requirements, including monitoring and measurement controls[67]. - The company has a structured approach to supplier qualification and procurement, ensuring that suppliers are vetted before entering the supplier database[65]. Financial Management - The total amount of funds raised through public stock issuance was approximately ¥1.23 billion, with a net amount of ¥1.16 billion after deducting issuance costs[113]. - The cumulative investment amount in fundraising projects reached approximately ¥605.94 million, representing a progress rate of 60.59%[113]. - The company plans to use up to ¥650 million of temporarily idle fundraising for cash management, investing in safe and liquid products[118]. - The company has invested approximately ¥10.82 billion in principal-protected financial products, with an outstanding balance of ¥1.49 billion[125]. - The company has issued structured deposits totaling ¥6 billion, with interest rates ranging from 1.3% to 3.29%[108].